Hematogones (medullar pro-B Cells) Are Present but Decreased in Active Multiple Myeloma and Are a Prognostic Factor in Treated Myeloma Patients
نویسندگان
چکیده
منابع مشابه
Prognostic Factors in Patients with Multiple Myeloma
That is why the morphology of myeloma cells is one of the most important prognostic factors of the disease [4]. There are also other prognostic factors associated with both malignant cell characteristics and the status of the host's immunocompetent system [7]. Taking into account the data on the decrease in colony-forming units granulocyte/macrophage (CFU-OM) in MM [2, 11], an~ the antitumor ef...
متن کاملMultiple Myeloma Update
This literature review presents the most recent developments in the management of multiple myeloma, which is characterized by the presence of abnormal plasma cells (myeloma cells) that accumulate into the bone marrow. Aspects related to pathophysiology, clinical manifestations, laboratory, study and treatment are described. These pieces of information are necessary to accomplish a better ...
متن کاملWhy better prognostic factors for multiple myeloma are needed.
T HE DURATION of survival of patients with multiple myeloma ranges from a few months to many years (median, 2.5 to 3 years). This range is wide, and both the patient and the physician would like to have a more precise prediction of survival for the individual patient. Furthermore, it is reasonable to consider more aggressive and more toxic therapy for the patient with prognostic factors that in...
متن کاملCD93 is Selectively Expressed on Human Myeloma Cells but Not on B Lymphocytes
Background: CD93 has originally been known as a C1q receptor, and many studies have demonstrated that CD93 is expressed on hematopoietic stem cells, B cell progenitors, myeloid and monocytic cells. Moreover, CD93 is shown to be expressed on long-lived plasma cells, and CD93 deficient-mice display an impairment in plasma cell development. Objective: To investiga...
متن کاملCirculating proteasome levels are an independent prognostic factor for survival in multiple myeloma.
The proteasome is a proteolytic complex for intracellular degradation of ubiquitinated proteins which are involved in cell-cycle regulation and apoptosis. A constitutively increased proteasome activity has been found in myeloma cells. We studied circulating proteasome levels and their prognostic significance in sera of 50 control subjects, 20 persons with monoclonal gammopathies of undetermined...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Blood
سال: 2014
ISSN: 0006-4971,1528-0020
DOI: 10.1182/blood.v124.21.2006.2006